To overcome the adverse effects associated with the use of STING agonists throughout the body and also the drug resistance of anti‐HER2 mAbs, we proposed targeted delivery of the STING agonists to tumor sites by binding to antibodies against HER‐2, which is overexpressed in multiple tumor types. The gene discussed is STING1; the disease is neoplasm.